188627-80-7 | Eptifibatide

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$9.00	$6.00
5mg	98%	in stock	$18.00	$13.00
50mg	98%	in stock	$51.00	$36.00

Description

• Catalog Number: AA66393
• Chemical Name: Eptifibatide
• CAS Number: 188627-80-7
• Molecular Formula: C35H49N11O9S2
• Molecular Weight: 831.9619
• MDL Number: MFCD05662245
• SMILES: OC(=O)C[C@@H]1NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@H](NC(=O)[C@H]2N(C(=O)[C@@H](NC1=O)Cc1c[nH]c3c1cccc3)CCC2)C(=O)N

Computed Properties

• Complexity: 1520
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 5
• Heavy Atom Count: 57
• Hydrogen Bond Acceptor Count: 12
• Hydrogen Bond Donor Count: 10
• Rotatable Bond Count: 10
• XLogP3: -2.4

Literature

• Inhibition of platelet-mediated arterial thrombosis and platelet granule exocytosis by 3',4'-dihydroxyflavonol and quercetin.

  Platelets 20130101

• Tirofiban versus abciximab: tirofiban is administered at suboptimal dosages when evaluated in an arterial thrombosis model in non-human primates.

  Clinical and experimental medicine 20121201

• The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.

  Drugs 20121112

• Efficiency of enrollment in a successful phase II acute stroke clinical trial.

  Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 20121101

• Comparison of abciximab versus eptifibatide during percutaneous coronary intervention in ST-segment elevation myocardial infarction (from the HORIZONS-AMI trial).

  The American journal of cardiology 20121001

• Peripartum management of dual antiplatelet therapy and neuraxial labor analgesia after bare metal stent insertion for acute myocardial infarction.

  Anesthesia and analgesia 20120901

• Perioperative management of a neurosurgical patient requiring antiplatelet therapy.

  Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20120901

• Safety of 'bridging' with eptifibatide for patients with coronary stents before cardiac and non-cardiac surgery.

  The American journal of cardiology 20120815

• Cost-effectiveness of adjunctive eptifibatide in patients undergoing coronary stenting in Germany.

  The European journal of health economics : HEPAC : health economics in prevention and care 20120801

• Perioperative management of a patient with recently placed drug-eluting stents requiring urgent spinal surgery.

  Journal of general internal medicine 20120801

• GP IIb/IIIa inhibitors for STEMI: still the gold standard or an old survivor?

  Current vascular pharmacology 20120701

• Intracoronary use of GP IIb/IIIa inhibitors in percutaneous coronary interventions.

  Current vascular pharmacology 20120701

• Eptifibatide for the treatment of HeartMate II left ventricular assist device thrombosis.

  Circulation. Heart failure 20120701

• Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of αIIb/β3 integrin.

  Blood 20120628

• Directing integrin-linked endocytosis of recombinant AAV enhances productive FAK-dependent transduction.

  Molecular therapy : the journal of the American Society of Gene Therapy 20120501

• Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: the INtegrilin plus STenting to Avoid myocardial Necrosis Trial.

  American heart journal 20120501

• Integrin α PAT-2/CDC-42 signaling is required for muscle-mediated clearance of apoptotic cells in Caenorhabditis elegans.

  PLoS genetics 20120501

• Mechanisms of Platelet Activation and Integrin αIIβ3.

  Korean circulation journal 20120501

• Adjusting eptifibatide doses for renal impairment: a model of dosing agreement among various methods of estimating creatinine clearance.

  The Annals of pharmacotherapy 20120401

• From snake venom toxins to therapeutics--cardiovascular examples.

  Toxicon : official journal of the International Society on Toxinology 20120315

• Routine upstream versus selective downstream administration of glycoprotein IIb/IIIa inhibitors in patients with non-ST-elevation acute coronary syndromes: a meta-analysis of randomized trials.

  International journal of cardiology 20120308

• A case of acute stent thrombosis during treatment with the thrombopoietin receptor agonist peptide--romiplostim.

  Heart, lung & circulation 20120301

• Bleeding risk and safety profile related to the use of eptifibatide: a current review.

  Expert opinion on drug safety 20120301

• Clinical outcomes of intracoronary eptifibatide bolus only versus intracoronary bolus and intravenous infusion of eptifibatide in primary percutaneous coronary intervention.

  Acute cardiac care 20120301

• Treatment with tirofiban for acute coronary syndrome (ACS): a systematic review and network analysis.

  Current medical research and opinion 20120301

• Bridging with glycoprotein IIb/IIIa inhibitors for periprocedural management of antiplatelet therapy in patients with drug eluting stents.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20120301

• Antiplatelet and anticoagulant drugs in interventional radiology.

  Cardiovascular and interventional radiology 20120201

• Contemporary use of glycoprotein IIb/IIIa inhibitors.

  Thrombosis and haemostasis 20120201

• Acute stent thrombosis: technical complication or inadequate antithrombotic therapy? An optical coherence tomography study.

  JACC. Cardiovascular interventions 20120201

• In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology.

  The Journal of clinical investigation 20120103

• Bridging therapy after recent stent implantation: case report and review of data.

  Cardiovascular revascularization medicine : including molecular interventions 20120101

• Mapuche herbal medicine inhibits blood platelet aggregation.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Incidence of bleeding in renally impaired patients receiving incorrectly dosed eptifibatide or bivalirudin while undergoing percutaneous coronary intervention.

  The Annals of pharmacotherapy 20120101

• Recent advances in epidural analgesia.

  Anesthesiology research and practice 20120101

• Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis.

  BMJ (Clinical research ed.) 20120101

• Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy.

  Cardiology research and practice 20120101

• Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty.

  Vascular health and risk management 20120101

• Eptifibatide-induced thrombocytopenia: with thrombosis and disseminated intravascular coagulation immediately after left main coronary artery percutaneous coronary angioplasty.

  Texas Heart Institute journal 20120101

• All-trans-retinoic acid ameliorated high fat diet-induced atherosclerosis in rabbits by inhibiting platelet activation and inflammation.

  Journal of biomedicine & biotechnology 20120101

• Integrins and their extracellular matrix ligands in lymphangiogenesis and lymph node metastasis.

  International journal of cell biology 20120101

• Summary of product characteristics (SmPC)--study on utilization of information presented in SmPC by different groups of physicians.

  Acta poloniae pharmaceutica 20120101

• Surface modification of biomaterials: a quest for blood compatibility.

  International journal of biomaterials 20120101

• [Coronary stenting and surgery: perioperative management of antiplatelet therapy in patients undergoing surgery after coronary stent implantation].

  Giornale italiano di cardiologia (2006) 20120101

• Platelets induce apoptosis during sepsis in a contact-dependent manner that is inhibited by GPIIb/IIIa blockade.

  PloS one 20120101

• Microvascular effect of intracoronary eptifibatide in acute myocardial infarction.

  Cardiology 20120101

• Mechanisms of xenogeneic baboon platelet aggregation and phagocytosis by porcine liver sinusoidal endothelial cells.

  PloS one 20120101

• Perioperative management of patients on clopidogrel (Plavix) undergoing major lung resection.

  The Annals of thoracic surgery 20111201

• The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial.

  American heart journal 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Mitral stenosis as a risk factor for embolic myocardial infarction--anticoagulation for some patients, individual treatment for all.

  Heart, lung & circulation 20111101

• Current issues with glycoprotein IIb-IIIa antagonists.

  Current drug targets 20111101

• Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.

  Annals of medicine 20111101

• Anticoagulant, anti-aggregation and antithrombotic effects of a novel hexapeptide.

  The Journal of pharmacy and pharmacology 20111101

• Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome.

  The American journal of cardiology 20111101

• Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function.

  American heart journal 20111101

• Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions.

  Drugs 20111022

• Lytic resistance of fibrin containing red blood cells.

  Arteriosclerosis, thrombosis, and vascular biology 20111001

• The original sin committed in years two thousand.

  Journal of interventional cardiology 20111001

• Effect of eptifibatide on platelet-mediated inflammation in acute coronary syndromes.

  International journal of cardiology 20110915

• [Diagnostic laparoscopy under dual antiplatelet therapy with clopidogrel and aspirin].

  Medizinische Klinik, Intensivmedizin und Notfallmedizin 20110901

• Advanced assessment of platelet function during adult donor care.

  Progress in transplantation (Aliso Viejo, Calif.) 20110901

• Integrilin in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction.

  Journal of interventional cardiology 20110801

• Successful microbubble sonothrombolysis without tissue-type plasminogen activator in a rabbit model of acute ischemic stroke.

  Stroke 20110801

• Poly-N-acetyl glucosamine fibers accelerate hemostasis in patients treated with antiplatelet drugs.

  The Journal of trauma 20110801

• Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.

  Circulation. Cardiovascular quality and outcomes 20110701

• Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab.

  Cardiovascular & hematological agents in medicinal chemistry 20110701

• Use of recombinant factor VIIa (NovoSeven(®)) in 8 patients with ongoing life-threatening bleeding treated with fondaparinux.

  Acute cardiac care 20110601

• Heparin promotes platelet responsiveness by potentiating αIIbβ3-mediated outside-in signaling.

  Blood 20110505

• Extended-infusion eptifibatide to prevent stent thrombosis in a patient undergoing orthopedic surgery.

  The Annals of pharmacotherapy 20110501

• Safety and feasibility of intraarterial eptifibatide as a revascularization tool in acute ischemic stroke.

  Journal of neurosurgery 20110401

• Induction of integrin β3 in PGE₂-stimulated adhesion of mastocytoma P-815 cells to the Arg-Gly-Asp-enriched fragment of fibronectin.

  Biochemical pharmacology 20110401

• Aortic root and valve thrombosis after implantation of a left ventricular assist device.

  The Journal of invasive cardiology 20110401

• Pharmacotherapy: NSTE ACS--benefit of concomitant eptifibatide and clopidogrel use before angiography?

  Nature reviews. Cardiology 20110401

• Update on glycoprotein IIb/IIIa: role in primary coronary intervention.

  Cardiovascular & hematological agents in medicinal chemistry 20110401

• Plasma concentrations of soluble CD40 ligand in smokers with acute myocardial infarction: a pilot study.

  Heart and vessels 20110301

• Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial.

  Circulation 20110222

• Intracoronary delivery of eptifibatide with the ClearWay® RX infusion catheter.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20110201

• The impact and management of acquired platelet dysfunction.

  Hamostaseologie 20110201

• Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy.

  Biomarkers in medicine 20110201

• Risk scores for patients with chest pain: evaluation in the emergency department.

  Current cardiology reviews 20110201

• Humanized mouse model of thrombosis is predictive of the clinical efficacy of antiplatelet agents.

  Circulation 20110125

• Meta-analysis of randomized trials of glycoprotein IIb/IIIa inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy.

  The American journal of cardiology 20110115

• Long-term efficacy of high-dose tirofiban versus double-bolus eptifibatide in patients undergoing percutaneous coronary intervention.

  Journal of cardiovascular medicine (Hagerstown, Md.) 20110101

• Post-resuscitation myocardial microcirculatory dysfunction is ameliorated with eptifibatide.

  Resuscitation 20110101

• A highly constrained cyclic (S,S)-CDC- peptide is a potent inhibitor of carotid artery thrombosis in rabbits.

  Platelets 20110101

• Cystine-knot peptides engineered with specificities for α(IIb)β(3) or α(IIb)β(3) and α(v)β(3) integrins are potent inhibitors of platelet aggregation.

  Journal of molecular recognition : JMR 20110101

• Atherosclerosis and thrombosis: insights from large animal models.

  Journal of biomedicine & biotechnology 20110101

• Fibrinolysis and Beyond: Bridging the Gap between Local and Systemic Clot Removal.

  Frontiers in neurology 20110101

• Effective management of acute coronary thrombosis in a young woman with lupus using aggressive medical therapy.

  Cardiology 20110101

• The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel.

  Thrombosis journal 20110101

• Variations on fibrinogen-erythrocyte interactions during cell aging.

  PloS one 20110101

• Left main stent thrombosis complicated by eptifibatide-induced acute thrombocytopenia.

  Texas Heart Institute journal 20110101

• Integrin targeted therapeutics.

  Theranostics 20110101

• Case of 'slow' stroke from carotid artery occlusion treated by delayed but cautious endovascular intervention.

  Stroke research and treatment 20110101

• Efficacy and safety of abciximab in diabetic patients who underwent percutaneous coronary intervention with thienopyridines loading: a meta-analysis.

  PloS one 20110101

• Endovascular implantation of covered stents in the extracranial carotid and vertebral arteries: Case series and review of the literature.

  Surgical neurology international 20110101

• Diabetes mellitus and cardiovascular prevention: the role and the limitations of currently available antiplatelet drugs.

  International journal of vascular medicine 20110101

• Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview.

  Vascular health and risk management 20110101

• Clopidogrel-induced neutropenia after coronary stenting: is cilostazol a good alternative?

  International journal of vascular medicine 20110101

• Implications of bleeding in acute coronary syndrome and percutaneous coronary intervention.

  Vascular health and risk management 20110101

• The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviors.

  PloS one 20110101

• The role of connective tissue growth factor (CTGF/CCN2) in skeletogenesis.

  Critical reviews in eukaryotic gene expression 20110101

• Emerging therapies for acute coronary syndromes.

  Frontiers in pharmacology 20110101

• Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation.

  BMC systems biology 20110101

• Novel agents for anti-platelet therapy.

  Journal of hematology & oncology 20110101

• Coronary perforation and covered stents: an update and review.

  Heart views : the official journal of the Gulf Heart Association 20110101

• Severe thrombocytopenia following tirofiban infusion.

  Indian journal of pharmacology 20110101

• [Percutaneous coronary angioplasty in women: clinical, procedural and prognostic features].

  The Pan African medical journal 20110101

• Critical appraisal of ticagrelor in the management of acute coronary syndrome.

  Therapeutics and clinical risk management 20110101

• Electron transfer dissociation coupled to an Orbitrap analyzer may promise a straightforward and accurate sequencing of disulfide-bridged cyclic peptides: a case study.

  Journal of mass spectrometry : JMS 20101201

• The evolving role of glycoprotein IIb/IIIa inhibitors in the setting of percutaneous coronary intervention strategies to minimize bleeding risk and optimize outcomes.

  JACC. Cardiovascular interventions 20101201

• Investigation of interaction of human platelet membrane components with anticoagulant drugs Abciximab and Eptifibatide.

  Folia histochemica et cytobiologica 20101201

• [Antiplatelet therapy in acute coronary syndromes: state of the art and new perspectives].

  Giornale italiano di cardiologia (2006) 20101201

• Review of Currently Available GP IIb/IIIa Inhibitors and Their Role in Peripheral Vascular Interventions.

  Seminars in interventional radiology 20101201

• Endothelium-derived but not platelet-derived protein disulfide isomerase is required for thrombus formation in vivo.

  Blood 20101125

• Laser-induced endothelial cell activation supports fibrin formation.

  Blood 20101125

• Dynamic regulation of fibrinogen: integrin αIIbβ3 binding.

  Biochemistry 20101102

• Impaired microvascular perfusion in sepsis requires activated coagulation and P-selectin-mediated platelet adhesion in capillaries.

  Intensive care medicine 20101101

• Clinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor.

  Journal of Korean medical science 20101101

• Long-term results following switch from abciximab to eptifibatide during percutaneous coronary intervention.

  Clinical cardiology 20101101

• Perspective on coronary interventions & cardiac surgeries in India.

  The Indian journal of medical research 20101101

• Snake venom disintegrins and cell migration.

  Toxins 20101101

• Making the right choice: optimizing rt-PA and eptifibatide lysis, an in vitro study.

  Thrombosis research 20101001

• Comparison of immediate vs early invasive strategy in patients with first acute non-ST-elevation myocardial infarction.

  Clinical cardiology 20101001

• Eptifibatide is noninferior to abciximab: implications for clinical practice.

  Nature reviews. Cardiology 20101001

• The role of proteomics in depression research.

  European archives of psychiatry and clinical neuroscience 20100901

• Atomic force microscopy-based molecular recognition of a fibrinogen receptor on human erythrocytes.

  ACS nano 20100824

• Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.

  Journal of the American College of Cardiology 20100803

• Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).

  Journal of the American College of Cardiology 20100803

• Balancing the benefits and risks of antiplatelet agents in patients with non-ST-segment elevated acute coronary syndromes and undergoing percutaneous coronary intervention.

  Journal of thrombosis and thrombolysis 20100801

• Vascular insights into the treatment of acute myocardial infarction by post-mortem in situ microcomputed tomography and histology.

  European heart journal 20100801

• Improved liquid chromatography-tandem mass spectrometry method for the analysis of eptifibatide in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100801

• Comparison of abciximab and eptifibatide on angiographic and clinical outcomes in rescue percutaneous coronary intervention for failed fibrinolytic therapy.

  The Journal of invasive cardiology 20100801

• Impact of bivalirudin therapy in high-risk patients with acute myocardial infarction: 1-year results from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial.

  JACC. Cardiovascular interventions 20100801

• Bivalirudin in acute myocardial infarction: 'primum non nocere': the eternal dilemma: balancing risks and benefits in high-risk patients.

  JACC. Cardiovascular interventions 20100801

• Comparison by meta-analysis of eptifibatide and tirofiban to abciximab in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention.

  The American journal of cardiology 20100715

• Comparison of catheterization laboratory initiated abciximab and eptifibatide during percutaneous coronary intervention in acute coronary syndromes (an ACUITY substudy).

  The American journal of cardiology 20100715

• What goes into a major acute coronary syndrome trial and what will future trials look like?

  Current cardiology reports 20100701

• Percutaneous cardiopulmonary support in refractory no-reflow with cardiogenic shock after coronary stenting in acute myocardial infarction.

  Yonsei medical journal 20100701

• Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial.

  European heart journal 20100701

• Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics.

  Clinical research in cardiology : official journal of the German Cardiac Society 20100601

• Anesthetic concerns for patients with coagulopathy.

  Current opinion in anaesthesiology 20100601

• Early administration of small-molecule glycoprotein IIb/IIIa inhibitors before primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from randomized clinical trials.

  Journal of cardiovascular pharmacology and therapeutics 20100601

• Update on antithrombotic therapy for stroke prevention in atrial fibrillation.

  Current treatment options in cardiovascular medicine 20100601

• The impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: results of the ACCEL-GENERIC study.

  The Korean journal of internal medicine 20100601

• Acute profound thrombocytopenia following eptifibatide administration.

  Southern medical journal 20100601

• Intra-arterial abciximab for the treatment of thrombus formation during coil embolization of intracranial aneurysms.

  Journal of neurointerventional surgery 20100601

• Combined mechanical and pharmacological approach to a thrombus-containing lesion.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20100501

• Quantitative determination of oxytocin receptor antagonist atosiban in rat plasma by liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100501

• Efficacy of enoxaparin, certoparin and dalteparin in preventing cardiac catheter thrombosis: an in vitro approach.

  Journal of thrombosis and thrombolysis 20100401

• Thromboembolic events associated with Neuroform stent in endovascular treatment of intracranial aneurysms.

  Journal of neuroimaging : official journal of the American Society of Neuroimaging 20100401

• Prolonged infusion of eptifibatide as bridge therapy between bare-metal stent insertion and cardiovascular surgery: case report and review of the literature.

  Pharmacotherapy 20100401

• RGD-ligand mimetic antagonists of integrin alphaIIbbeta3 paradoxically enhance GPVI-induced human platelet activation.

  Journal of thrombosis and haemostasis : JTH 20100301

• Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.

  Circulation 20100216

• Delivery of glycoprotein IIb/IIIa inhibitor therapy for percutaneous coronary intervention: why not take the intracoronary highway?

  Circulation 20100216

• [The EARLY ACS study].

  Giornale italiano di cardiologia (2006) 20100201

• [Don't throw the baby out with the bathwater. Treatment of acute coronary syndrome].

  Giornale italiano di cardiologia (2006) 20100201

• Regulation of CD40L (CD154) and CD62P (p-selectin) surface expression upon GPIIb-IIIa blockade of platelets from stable coronary artery disease patients.

  Thrombosis research 20100101

• Platelet thrombin receptor antagonism and atherothrombosis.

  European heart journal 20100101

• Using ImageJ for the quantitative analysis of flow-based adhesion assays in real-time under physiologic flow conditions.

  Platelets 20100101

• A prospective evaluation of the safety and efficacy of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions: design and statistical methods of the PERSEUS clinical program.

  Trials 20100101

• Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients.

  Thrombosis and haemostasis 20100101

• The PFA-100R cannot detect blood group-dependent inhibition of platelet function by eptifibatide or abciximab at therapeutic plasma concentrations.

  Platelets 20100101

• Emergency neurological care of strokes and bleeds.

  Journal of emergencies, trauma, and shock 20100101

• In-stent thrombosis after 68 months of implantation inspite of continuous dual antiplatelet therapy: a case report.

  Cases journal 20100101

• Safety and efficacy of thrombectomy in patients undergoing primary percutaneous coronary intervention for acute ST elevation MI: a meta-analysis of randomized controlled trials.

  BMC cardiovascular disorders 20100101

• Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention.

  Vascular health and risk management 20100101

• Acute transient phlebitis during eptifibatide intravenous injection: case report.

  Heart & lung : the journal of critical care 20100101

• Unusual towering elevation of troponin I after ST-elevation myocardial infarction and intensive monitoring with echocardiography post-percutaneous coronary intervention: a case report.

  Journal of medical case reports 20100101

• Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia.

  Biomarker insights 20100101

• Deep vein thrombosis and pulmonary embolism - Prevention, management, and anaesthetic considerations.

  Indian journal of anaesthesia 20100101

• Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor.

  Vascular health and risk management 20100101

• Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis.

  BMC medicine 20100101

• Multiple recurrent stent thrombosis in a patient with coexisting clopidogrel resistance and increased anticardiolipin antibodies: a case report.

  Case reports in medicine 20100101

• Acute chest pain: Acute coronary syndrome versus lead perforation: A case report.

  International archives of medicine 20100101

• Actual Role of Platelet Glycoprotein IIb/IIIa Receptor Inhibitors as Adjunctive Pharmacological Therapy to Primary Angioplasty in Acute Myocardial Infarction: In the Light of Recent Randomized Trials and Observational Studies with Bivalirudin.

  The open cardiovascular medicine journal 20100101

• Left ventricular rupture due to HIV-associated T-cell lymphoma.

  Texas Heart Institute journal 20100101

• Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome.

  Drug design, development and therapy 20100101

• GPIIb/IIIa Receptor Antagonism Using Small Molecules Provides no Additive Long-Term Protection after Percutaneous Coronary Intervention as Compared to Clopidogrel Plus Aspirin.

  The open cardiovascular medicine journal 20100101

• Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update.

  Vascular health and risk management 20100101

• Characterization of human platelet binding of recombinant T cell receptor ligand.

  Journal of neuroinflammation 20100101

• Assessment of eptifibatide clearance by hemodialysis using an in vitro system.

  Blood purification 20100101

• The effect of tobacco smoking and treatment strategy on the one-year mortality of patients with acute non-ST-segment elevation myocardial infarction.

  BMC cardiovascular disorders 20100101

• Primary PCI for acute anterior wall MI with pulmonary edema and left anterior descending artery ostial stenosis.

  Indian heart journal 20100101

• Dual antiplatelet therapy in secondary prevention of ischemic stroke: a ghost from the past or a new frontier?

  Stroke research and treatment 20100101

• Targeting the platelet integrin GPIIb/IIIa.

  Current pharmaceutical design 20100101

• Newer antithrombotic drugs.

  Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine 20100101

• Profound thrombocytopenia after primary exposure to eptifibatide.

  Drug, healthcare and patient safety 20100101

• Structure and function of snake venom proteins affecting platelet plug formation.

  Toxins 20100101

• Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention.

  JAMA 20091209

• Impact of computerized dosing on eptifibatide-associated bleeding and mortality.

  American heart journal 20091201

• The GPIIbIIIa antagonist drugs eptifibatide and tirofiban do not induce activation of apoptosis executioner caspase-3 in resting platelets but inhibit caspase-3 activation in platelets stimulated with thrombin or calcium ionophore A23187.

  Haematologica 20091201

• The significance of clopidogrel low-responsiveness on stent thrombosis and cardiac death assessed by the verifynow p(2)y(12) assay in patients with acute coronary syndrome within 6 months after drug-eluting stent implantation.

  Korean circulation journal 20091201

• Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study.

  Journal of thrombosis and thrombolysis 20091101

• Safety, effectiveness, and practicality of endovascular therapy within the first 3 hours of acute ischemic stroke onset.

  Neurosurgery 20091101

• Safety of eptifibatide for subcortical stroke progression.

  Cerebrovascular diseases (Basel, Switzerland) 20091101

• Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials.

  European heart journal 20091101

• Glycoprotein IIb/IIIa antagonists: new developments.

  Hamostaseologie 20091101

• [Use of eptifibatide in patients with acute stent thrombosis, requiring urgent surgical revascularisation - report of 2 cases].

  Kardiologia polska 20091101

• Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20091001

• Safety and effectiveness of endovascular therapy after 8 hours of acute ischemic stroke onset and wake-up strokes.

  Stroke 20091001

• Complications and controversies of regional anaesthesia: a review.

  Indian journal of anaesthesia 20091001

• Integrin priming dynamics: mechanisms of integrin antagonist-promoted alphaIIbbeta3:PAC-1 molecular recognition.

  Biochemistry 20090908

• Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial.

  Lancet (London, England) 20090905

• Considering usual medical care in clinical trial design.

  PLoS medicine 20090901

• Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia.

  Blood 20090806

• Effect of operator and institutional volume on clinical outcomes after percutaneous coronary interventions performed in Canada and the United States: a brief report from the Enhanced Suppression of the Platelet glycoprotein IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) study.

  The Canadian journal of cardiology 20090801

• Balancing potency of platelet inhibition with bleeding risk in the early treatment of acute coronary syndrome.

  The western journal of emergency medicine 20090801

• Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST).

  Circulation. Cardiovascular interventions 20090801

• Spontaneous recanalization of a completely occluded saphenous vein graft two months following acute myocardial infarction with persistent one year patency.

  Journal of thrombosis and thrombolysis 20090701

• Acute profound thrombocytopenia associated with readministration of eptifibatide: case report and review of the literature.

  Pharmacotherapy 20090701

• Binding of plasma factor XIII to thrombin-receptor activated human platelets.

  Thrombosis and haemostasis 20090701

• Timing and duration of myocardial ischemia on Holter monitoring following percutaneous coronary intervention and their association with clinical outcomes (a PROTECT-TIMI 30 Substudy Analysis).

  The American journal of cardiology 20090701

• Facilitated angioplasty with combo therapy among patients with ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.

  The American journal of emergency medicine 20090701

• Effect of left ventricular hypertrophy on long-term survival of patients with coronary artery disease following percutaneous coronary intervention.

  Heart international 20090630

• Hotline sessions presented at the American College of Cardiology Congress 2009.

  Clinical research in cardiology : official journal of the German Cardiac Society 20090601

• Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.

  The Journal of invasive cardiology 20090601

• Provisional use of glycoprotein IIb/IIIa inhibitors in the era of dual antiplatelet therapy--do 'bailouts' pay off?

  The Journal of invasive cardiology 20090601

• Variability of platelet aggregate dispersal with glycoprotein IIb-IIIa antagonists eptifibatide and abciximab.

  Journal of thrombosis and haemostasis : JTH 20090601

• A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.

  Circulation. Cardiovascular interventions 20090601

• Switch from abciximab to eptifibatide during percutaneous coronary intervention.

  International journal of cardiology 20090529

• Early versus delayed, provisional eptifibatide in acute coronary syndromes.

  The New England journal of medicine 20090521

• Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis.

  Journal of the American College of Cardiology 20090505

• The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect?

  Journal of the American College of Cardiology 20090505

• Association between increased platelet P-selectin expression and obesity in patients with type 2 diabetes: a BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy.

  Diabetes care 20090501

• Adjunctive intracoronary antithrombotic therapy: time to revisit an old strategy?

  The Journal of invasive cardiology 20090501

• Adhesion of Plasmodium falciparum-infected erythrocytes to human cells: molecular mechanisms and therapeutic implications.

  Expert reviews in molecular medicine 20090501

• Point-of-care assessment of antiplatelet agents in the perioperative period: a review.

  Anaesthesia and intensive care 20090501

• Perioperative management of antiplatelet-drugs in cardiac surgery.

  Current cardiology reviews 20090501

• Empty microcatheter technique for the deployment of a self-expanding stent to treat refractory middle cerebral artery occlusion in the setting of severe proximal tortuosity.

  Journal of neuroimaging : official journal of the American Society of Neuroimaging 20090401

• Management of patients with unstable angina / non-ST-elevation myocardial infarction: a critical review of the 2007 ACC /AHA guidelines.

  International journal of clinical practice 20090401

• Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions.

  Diabetes care 20090401

• Cost-effectiveness analysis of anticoagulation strategies in non-ST-elevation acute coronary syndromes.

  The Annals of pharmacotherapy 20090401

• Spontaneous coronary artery dissection and severe hypothyroidism.

  The Journal of invasive cardiology 20090401

• Adjunctive Pharmacotherapy Part II.

  The Journal of invasive cardiology 20090401

• Characterization of static adhesion of human platelets in plasma to protein surfaces in microplates.

  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20090401

• Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.

  Journal of the American College of Cardiology 20090310

• Optimal antiplatelet therapy during percutaneous coronary interventions includes glycoprotein IIb/IIIa inhibitors just eliminate the infusion.

  Journal of the American College of Cardiology 20090310

• Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain.

  The Journal of clinical investigation 20090302

• Streamlining the design of promising clinical trials: in-vitro testing of antithrombotic regimens and multiple agonists of platelet activation.

  Coronary artery disease 20090301

• Focus on adjunctive pharmacotherapy to improve outcomes of percutaneous coronary intervention.

  The Journal of invasive cardiology 20090301

• Administration of eptifibatide during transfer for primary PCI in patients with STEMI: effect on Pre-PCI TIMI flow and its correlation with pain-to-therapy time.

  The Journal of invasive cardiology 20090301

• Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation.

  Thrombosis and haemostasis 20090301

• Prevention and treatment of thromboembolism during endovascular aneurysm therapy.

  Klinische Neuroradiologie 20090301

• Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study.

  Journal of the American College of Cardiology 20090224

• Determination of eptifibatide concentration in human plasma utilizing the liquid chromatography-tandem mass spectrometry method.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090215

• Eptifibatide does not suppress the increase of inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome.

  Journal of thrombosis and thrombolysis 20090201

• Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20090201

• The benefits and risks of abciximab, eptifibatide, or tirofiban during PCI: class effects or do they differ?

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20090201

• Acute profound thrombocytopenia with second exposure to eptifibatide associated with a strong antibody reaction.

  Platelets 20090201

• Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trial.

  Circulation. Cardiovascular interventions 20090201

• Eptifibatide overdose.

  International journal of cardiology 20090124

• Species differences in small molecule binding to alpha IIb beta 3 are the result of sequence differences in 2 loops of the alpha IIb beta propeller.

  Blood 20090122

• Effect of low frequency ultrasound on combined rt-PA and eptifibatide thrombolysis in human clots.

  Thrombosis research 20090101

• Analysis of adenoviral attachment to human platelets.

  Virology journal 20090101

• Comparison of VerifyNow-P2Y12 test and Flow Cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel therapy?

  Thrombosis journal 20090101

• Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization.

  Vascular health and risk management 20090101

• Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction.

  Vascular health and risk management 20090101

• Safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention.

  Texas Heart Institute journal 20090101

• Clopidogrel resistance 'Live' - the risk of stent thrombosis should be evaluated before procedures.

  Thrombosis journal 20090101

• The in vitro effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.

  Acta poloniae pharmaceutica 20090101

• Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention.

  Vascular health and risk management 20090101

• Thrombelastography and tromboelastometry in assessing coagulopathy in trauma.

  Scandinavian journal of trauma, resuscitation and emergency medicine 20090101

• Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration.

  Trials 20090101

• A retrospective analysis and case series of glycoprotein IIb/IIIa inhibitor associated diffuse alveolar hemorrhage: two case reports.

  Cases journal 20090101

• Antiplatelet drugs and the perioperative period: What every urologist needs to know.

  Indian journal of urology : IJU : journal of the Urological Society of India 20090101

• The roles of platelet GPIIb/IIIa and alphavbeta3 integrins during HeLa cells adhesion, migration, and invasion to monolayer endothelium under static and dynamic shear flow.

  Journal of biomedicine & biotechnology 20090101

• Drug-induced hematologic syndromes.

  Advances in hematology 20090101

• Drug-induced thrombocytopenia: pathogenesis, evaluation, and management.

  Hematology. American Society of Hematology. Education Program 20090101

• An unusual case of spontaneous multi vessel coronary artery dissection in an elderly patient: a case report.

  Cases journal 20090101

• Is anti-platelet therapy interruption a real clinical issue? Its implications in dentistry and particularly in periodontics.

  Journal of Indian Society of Periodontology 20090101

• Antiplatelet Resistance-Does it Exist and How to Measure it?

  Clinical medicine. Cardiology 20090101

• Acute coronary syndrome in pregnancy.

  Clinical medicine. Cardiology 20090101

• Eptifibatide: The evidence for its role in the management of acute coronary syndromes.

  Core evidence 20090101

• Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis.

  Heart (British Cardiac Society) 20081201

• The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial.

  Stroke 20081201

• Profound thrombocytopenia with glycoprotein IIb/IIIa inhibitors plus heparin for pump thrombus.

  The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20081201

• The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome.

  Journal of interventional cardiology 20081201

• The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.

  JACC. Cardiovascular interventions 20081201

• The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary.

  Current cardiology reviews 20081101

• Rescue treatment with intra-arterial tirofiban infusion and emergent carotid stenting.

  Yonsei medical journal 20081031

• Distal myocardial protection with intracoronary beta blocker when added to a Gp IIb/IIIa platelet receptor blocker during percutaneous coronary intervention improves clinical outcome.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20081001

• Comparison of bivalirudin, enoxaparin, and unfractionated heparin in preventing cardiac catheter thrombosis. Results of an in-vitro study.

  Thrombosis and haemostasis 20081001

• Bleeding and outcome in acute coronary syndrome: insights from continuous electrocardiogram monitoring in the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial.

  American heart journal 20081001

• A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial.

  Journal of cardiovascular medicine (Hagerstown, Md.) 20080901

• GP IIb/IIIa inhibitors during primary percutaneous coronary intervention for STEMI: new trial and registry data.

  Current cardiology reports 20080901

• Bolus-only versus bolus + infusion of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.

  American heart journal 20080901

• Hemorrhagic pericarditis with cardiac tamponade after percutaneous coronary intervention associated with the use of abciximab.

  The Korean journal of internal medicine 20080901

• Local intra-arterial eptifibatide for intraoperative vessel thrombosis during aneurysm coiling.

  AJNR. American journal of neuroradiology 20080801

• A multicenter, randomized, open-label, therapeutic, and exploratory trial to evaluate the tolerability and efficacy of platelet glycoprotein IIb/IIIa receptor blocker (Clotinab) in high-risk patients with percutaneous coronary intervention.

  Yonsei medical journal 20080630

• Treatment-competing events in dynamic regimes.

  Lifetime data analysis 20080601

• Functional and computational studies of the ligand-associated metal binding site of beta3 integrins.

  Proteins 20080601

• In-vitro comparison of fondaparinux, unfractionated heparin, and enoxaparin in preventing cardiac catheter-associated thrombus.

  Coronary artery disease 20080601

• Utilization of GP IIb/IIIa inhibitors in peripheral percutaneous interventions: current applications and in-hospital outcomes at a tertiary referral center.

  The Journal of invasive cardiology 20080601

• Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  Chest 20080601

• Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin.

  Vascular health and risk management 20080601

• Antiplatelet drugs in cardiological practice: established strategies and new developments.

  Vascular health and risk management 20080601

• Pharmacological and mechanical revascularization strategies in STEMI: integration of the two approaches.

  The Journal of invasive cardiology 20080501

• Drug-eluting stent implantation for acute myocardial infarction during pregnancy with use of glycoprotein IIb/IIIa inhibitor, aspirin and clopidogrel.

  The Journal of invasive cardiology 20080501

• The Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept?

  Current cardiology reviews 20080501

• Eptifibatide-induced thrombocytopenia.

  Journal of thrombosis and thrombolysis 20080401

• Low-pressure balloon angioplasty with adjuvant pharmacological therapy in patients with acute ischemic stroke caused by intracranial arterial occlusions.

  Neuroradiology 20080401

• Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy.

  Journal of interventional cardiology 20080401

• Real-world safety and efficacy of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.

  The Journal of invasive cardiology 20080301

• Abciximab: a reappraisal of its use in coronary care.

  Biologics : targets & therapy 20080301

• Rescue use of tirofiban for acute carotid in-stent thrombosis.

  Yonsei medical journal 20080227

• The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention.

  Journal of the American College of Cardiology 20080205

• The safety and efficacy of glycoprotein IIb/IIIa inhibitors for primary angioplasty: more options to choose and more time to decide.

  Journal of the American College of Cardiology 20080205

• Application of high-throughput screening to identify a novel alphaIIb-specific small- molecule inhibitor of alphaIIbbeta3-mediated platelet interaction with fibrinogen.

  Blood 20080201

• High-dose tirofiban administered as bolus-only during percutaneous coronary intervention.

  The Journal of invasive cardiology 20080201

• ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy.

  The American journal of emergency medicine 20080201

• [Acute profound thrombocytopenia associated with tirofiban: clinical approach to diagnosis and therapeutic management].

  Giornale italiano di cardiologia (2006) 20080201

• A review of cardiogenic shock in acute myocardial infarction.

  Current cardiology reviews 20080201

• Emergency coronary artery bypass grafting in patients with acute myocardial infarction treated with glycoprotein IIb/IIIa receptor inhibitors.

  International journal of cardiology 20080124

• Complications of Neuroform stent in endovascular treatment of intracranial aneurysms.

  Neurocritical care 20080101

• Postprocedure intravenous eptifibatide following intra-arterial reteplase in patients with acute ischemic stroke.

  Journal of neuroimaging : official journal of the American Society of Neuroimaging 20080101

• Platelet GPIIb/IIIa receptor antagonists in human ischemic brain disease.

  Current vascular pharmacology 20080101

• The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects.

  PPAR research 20080101

• Platelet anaesthesia during extracorporeal circulation: differential effects of GP IIb/IIIa blockers on platelet activation marker P-selectin expression at hypothermia.

  Thrombosis research 20080101

• Glycoprotein IIb/IIIa antagonists in acute ischaemic stroke: current status and future directions.

  Drugs 20080101

• A longitudinal analysis of outcomes associated with abciximab and eptifibatide in a consecutive series of 3074 percutaneous coronary interventions.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20080101

• Glycoprotein IIb/IIIa inhibitors in patients with renal insufficiency undergoing percutaneous coronary intervention.

  Cardiology in review 20080101

• Diagnostic uncertainty of Takotusbo cardiomyopathy in a woman with cardiovascular risk factors hijacked at gunpoint: a case report.

  Cases journal 20080101

• Plateletworks: a novel point of care platelet function screen.

  Molecular diagnosis & therapy 20080101

• Cardiovascular magnetic resonance of scar and ischemia burden early after acute ST elevation and non-ST elevation myocardial infarction.

  Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20080101

• Successful catheter ablation of persistent electrical storm late post myocardial infarction by targeting purkinje arborization triggers.

  Indian pacing and electrophysiology journal 20080101

• Ultrasound enhanced prehospital thrombolysis using microbubbles infusion in patients with acute ST elevation myocardial infarction: rationale and design of the Sonolysis study.

  Trials 20080101

• Eptifibatide and abciximab inhibit insulin-induced focal adhesion formation and proliferative responses in human aortic smooth muscle cells.

  Cardiovascular diabetology 20080101

• Phase I study of eptifibatide in patients with sickle cell anaemia.

  British journal of haematology 20071101

• Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention.

  The American journal of cardiology 20071101

• Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists.

  Platelets 20071101

• Glycoprotein IIb/IIIa antagonists during carotid artery stenting: results from the carotid artery stenting (CAS) registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK).

  Clinical research in cardiology : official journal of the German Cardiac Society 20071001

• Efficacy and safety of triple antiplatelet therapy with and without concomitant anticoagulation during elective percutaneous coronary intervention (the REMOVE trial).

  The American journal of cardiology 20071001

• Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention.

  The Canadian journal of cardiology 20071001

• [Massive pulmonary embolism mimicking ST-elevation acute coronary syndrome successfully treated with hybrid therapy in a trauma patient receiving nadroparin: diagnostic and therapeutic dilemmas].

  Kardiologia polska 20071001

• Beta2-integrins and acquired glycoprotein IIb/IIIa (GPIIb/IIIa) receptors cooperate in NF-kappaB activation of human neutrophils.

  The Journal of biological chemistry 20070921

• Assessment of eptifibatide dosing in renal impairment before and after in-service education provided by pharmacists.

  Journal of managed care pharmacy : JMCP 20070901

• Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils.

  Arteriosclerosis, thrombosis, and vascular biology 20070801

• Optimal platelet inhibition in patients undergoing PCI: data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study.

  American heart journal 20070801

• Immediate and intermediate results of intracoronary stand-alone bolus administration of eptifibatide during coronary intervention (ICE) study.

  American heart journal 20070801

• A randomised controlled trial of upstream administration of eptifibatide in patients presenting non-ST segment elevation acute coronary syndrome treated with an invasive strategy.

  EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20070801

• Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20070701

• Impact of iodinated contrast injections on percent diameter coronary arterial stenosis and implications for trials of intracoronary pharmacotherapies in patients with ST-elevation myocardial infarction.

  The American journal of cardiology 20070701

• Association of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention (A REPLACE-2 analysis).

  The American journal of cardiology 20070615

• Elevated plasma fibrinogen level predicts suboptimal response to therapy with both single- and double-bolus eptifibatide during percutaneous coronary intervention.

  Journal of the American College of Cardiology 20070605

• The role of eptifibatide in patients undergoing percutaneous coronary intervention.

  Expert opinion on pharmacotherapy 20070601

• The direct thrombin inhibitor argatroban: a review of its use in patients with and without HIT.

  Biologics : targets & therapy 20070601

• Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).

  The American journal of cardiology 20070515

• Present and evolving role of eptifibatide in the treatment of acute coronary syndromes.

  Expert review of cardiovascular therapy 20070501

• Middle cerebral artery stenting for acute ischemic stroke after unsuccessful Merci retrieval.

  Neurosurgery 20070401

• Current strategies with high-dose tirofiban.

  Expert opinion on drug metabolism & toxicology 20070401

• Enoxaparin injection for the treatment of high-risk patients with non-ST elevation acute coronary syndrome.

  Vascular health and risk management 20070401

• AlphaIIbbeta3 priming and clustering by orally active and intravenous integrin antagonists.

  Journal of thrombosis and haemostasis : JTH 20070301

• Current incidence and clinical outcomes of bivalirudin administration among patients undergoing primary coronary intervention for stent thrombosis elevation acute myocardial infarction.

  Coronary artery disease 20070301

• Preoperative platelet inhibition with eptifibatide during coronary artery bypass grafting with cardiopulmonary bypass.

  Journal of cardiovascular pharmacology and therapeutics 20070301

• Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?

  Journal of the American College of Cardiology 20070213

• [Update on antithrombotic treatments in arterial diseases].

  Revue medicale suisse 20070207

• Bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in drug-eluting stent implantations in the absence of acute myocardial infarction: clinical and economic results.

  The Journal of invasive cardiology 20070201

• Eptifibatide vs abciximab as adjunctive therapy during primary percutaneous coronary intervention for acute myocardial infarction.

  Mayo Clinic proceedings 20070201

• Prolonged intravenous eptifibatide infusion for prevention of coronary stent thrombosis.

  International journal of cardiology 20070118

• Clinical outcomes comparing eptifibatide and abciximab in ST elevation acute myocardial infarction patients undergoing percutaneous coronary interventions.

  Cardiology 20070101

• Rapid disappearance of an endothelial ulceration in the left main coronary artery.

  Cardiology 20070101

• Role of antiplatelets in carotid artery stenting.

  Stroke 20070101

• The integrins.

  Genome biology 20070101

• Utility of PFA-100 closure time vs. optical aggregometry in assessing the efficacy of platelet membrane glycoprotein IIb/IIIa antagonists in vitro.

  Clinical chemistry and laboratory medicine 20070101

• Systemic reperfusion therapy in acute ischemic stroke.

  Cerebrovascular diseases (Basel, Switzerland) 20070101

• A review of clinical trials with eptifibatide in cardiology.

  Cardiovascular drug reviews 20070101

• [Von Willebrand factor and soluble P-selectin in patients with non ST-Elevation acute coronary syndrome during treatment with glycoprotein IIb/IIIa antagonist eptifibatide].

  Kardiologiia 20070101

• Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study.

  Journal of the American College of Cardiology 20061205

• Delayed profound thrombocytopenia associated with eptifibatide.

  American journal of hematology 20061201

• Safety and efficacy of low-dose unfractionated heparin during percutaneous coronary revascularisation and the relationship between activated clotting time and haemorrhagic or ischaemic complications: our results.

  Journal of cardiovascular medicine (Hagerstown, Md.) 20061201

• Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba.

  Thrombosis and haemostasis 20061201

• PCI with and without abciximab after upstream eptifibatide use: outcomes in high-risk patients.

  The Journal of invasive cardiology 20061201

• Bivalirudin in percutaneous coronary intervention.

  Vascular health and risk management 20061201

• Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI).

  Vascular health and risk management 20061201

• [Antithrombotic treatment of acute coronary syndromes without ST-segment elevation].

  Deutsche medizinische Wochenschrift (1946) 20061124

• Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention.

  The Journal of invasive cardiology 20061101

• Bolus-only glycoprotein IIb/IIIa inhibitor revisited.

  The Journal of invasive cardiology 20061101

• Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial.

  American heart journal 20061001

• Unfractionated heparin reduces the anti-platelet effects of abciximab but not eptifibatide during PCI.

  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20061001

• Eptifibatide-induced thrombocytopenia and thrombosis.

  Journal of thrombosis and thrombolysis 20061001

• Initial experience with the use of intravenous eptifibatide bolus during endovascular treatment of intracranial aneurysms.

  AJNR. American journal of neuroradiology 20061001

• High-dose, single-bolus eptifibatide: a safe and cost-effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventions.

  The Journal of invasive cardiology 20061001

• Commentary: Alternative safe, effective and cost-efficient dosing for eptifibatide in low-risk patients.

  The Journal of invasive cardiology 20061001

• [Platelet and tissue factor: review].

  Zhongguo shi yan xue ye xue za zhi 20061001

• Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative.

  Circulation 20060926

• Role of abciximab in the treatment of coronary artery disease.

  Expert opinion on biological therapy 20060901

• Eptifibatide-eluting stent as an antiproliferative and antithrombotic agent: in vitro evaluation.

  The Journal of invasive cardiology 20060901

• Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20060801

• Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina.

  Journal of thrombosis and thrombolysis 20060801

• C-reactive protein promotes platelet adhesion to endothelial cells: a potential pathway in atherothrombosis.

  British journal of haematology 20060801

• Complementary effects of sirolimus-eluting stents and glycoprotein IIb/IIIa inhibitors for percutaneous coronary intervention in diabetic patients: one-year follow up of a single-centre registry.

  Heart (British Cardiac Society) 20060801

• Greater inhibitory effects of bivalirudin compared with unfractionated heparin plus eptifibitide on thrombin-induced platelet activation.

  Coronary artery disease 20060801

• Alveolar hemorrhage: an underdiagnosed complication of treatment with glycoprotein IIb/IIIa inhibitors.

  Journal of interventional cardiology 20060801

• Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets.

  Circulation research 20060707

• In vitro effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with aspirin, eptifibatide, tirofiban, enoxaparin or alteplase on haemostatic parameters.

  Life sciences 20060620

• A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.

  Journal of the American College of Cardiology 20060620

• Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial.

  Journal of the American College of Cardiology 20060620

• The future of an illusion.

  Journal of the American College of Cardiology 20060620

• Self-expanding stent-assisted middle cerebral artery recanalization: technical note.

  Neuroradiology 20060601

• Anticoagulant and antiplatelet medications.

  Critical care nurse 20060601

• Cold leg in patient with high coated platelets: possible association with the use of rofecoxib.

  The Journal of invasive cardiology 20060601

• Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome.

  The American journal of cardiology 20060515

• Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary intervention.

  Pharmacotherapy 20060501

• [Acute coronary syndrome: peri-interventional antithrombotic therapy].

  Hamostaseologie 20060501

• Suspected clopidogrel resistance in a patient with acute stent thrombosis.

  Nature clinical practice. Cardiovascular medicine 20060401

• Treating the acute stroke patient as an emergency: current practices and future opportunities.

  International journal of clinical practice 20060401

• (N)-methanocarba-2MeSADP (MRS2365) is a subtype-specific agonist that induces rapid desensitization of the P2Y1 receptor of human platelets.

  Journal of thrombosis and haemostasis : JTH 20060401

• Tirofiban (Aggrastat) protects platelets and decreases platelet-granulocyte binding in an extracorporeal circulation model.

  The Thoracic and cardiovascular surgeon 20060401

• Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors.

  Journal of thrombosis and haemostasis : JTH 20060301

• Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia.

  Pharmacotherapy 20060301

• Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients: an ex vivo human study.

  Thrombosis and haemostasis 20060301

• Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis.

  Thrombosis and haemostasis 20060301

• Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?

  Vascular health and risk management 20060301

• Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.

  Journal of the American College of Cardiology 20060221

• The value of selectivity.

  Journal of the American College of Cardiology 20060221

• Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention.

  The American journal of cardiology 20060215

• The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.

  Journal of the American College of Cardiology 20060207

• Upstream/downstream glycoprotein IIb/IIIa in non-ST-segment elevation myocardial infarction.

  Journal of the American College of Cardiology 20060207

• Increased ability of tirofiban to maintain its inhibitory effects on the binding of fibrinogen to platelets in blood from patients with and without diabetes mellitus.

  Coronary artery disease 20060201

• Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists.

  The American journal of cardiology 20060201

• Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial.

  American heart journal 20060201

• Glycoprotein IIb/IIIa inhibitors during rescue percutaneous coronary intervention in acute myocardial infarction.

  The Journal of invasive cardiology 20060201

• Recurrent acute profound thrombocytopenia related to readministration of eptifibatide.

  Journal of interventional cardiology 20060201

• Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.

  Thrombosis research 20060101

• Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin.

  Thrombosis research 20060101

• Tirofiban for the treatment of ischaemic stroke.

  Expert opinion on pharmacotherapy 20060101

• Eptifibatide in peripheral vascular interventions: results of the Integrilin Reduces Inflammation in Peripheral Vascular Interventions (INFLAME) trial.

  The Journal of invasive cardiology 20060101

• Thrombosis, inflammation, and our evolving understanding of vascular biology during interventional therapy.

  The Journal of invasive cardiology 20060101

• Platelet receptors.

  AJNR. American journal of neuroradiology 20060101

• Spotlight on eptifibatide in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.

  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20060101

• [Glycoprotein IIb/IIIa antagonist eptifibatide in acute coronary syndrome without elevation of ST segment].

  Kardiologiia 20060101

• Acute ischemic heart disease and interventional cardiology: a time for pause.

  BMC medicine 20060101

• An audit of the use and complications of glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention against national UK standards.

  Cardiovascular revascularization medicine : including molecular interventions 20060101

• A comparative study on the cost of new antibiotics and drugs of other therapeutic categories.

  PloS one 20060101

• Effects of GP IIb/IIIa inhibitors on vascular inflammation, coronary microcirculation, and platelet function.

  Reviews in cardiovascular medicine 20060101

• Glycoprotein IIb-IIIa receptor inhibition with eptifibatide in percutaneous intervention for symptomatic peripheral vascular disease: the circulate pilot trial.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20051201

• Administration of intracoronary eptifibatide during ST-elevation myocardial infarction.

  The American journal of cardiology 20051201

• Successful management of the no-reflow syndome after venous graft stenting.

  The Journal of invasive cardiology 20051201

• Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes.

  Expert opinion on drug metabolism & toxicology 20051201

• Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial.

  European heart journal 20051001

• Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention.

  The Annals of pharmacotherapy 20051001

• Initial experience with a new femoral artery closure device following percutaneous coronary intervention with glycoprotein IIb/IIIa inhibition.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20051001

• Microparticles from apoptotic vascular smooth muscle cells induce endothelial dysfunction, a phenomenon prevented by beta3-integrin antagonists.

  Thrombosis and haemostasis 20051001

• The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention.

  Coronary artery disease 20050901

• Pharmacologic cerebral capillary blood flow improvement after deep hypothermic circulatory arrest: an intravital fluorescence microscopy study in pigs.

  The Journal of thoracic and cardiovascular surgery 20050901

• Impact of platelet glycoprotein IIb/IIIa Inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy).

  The American journal of cardiology 20050815

• The effect of glycoprotein IIIa PIA 1/A2 polymorphism on the PFA-100 response to GP IIb IIa receptor inhibitors-the importance of anticoagulants used.

  Journal of thrombosis and thrombolysis 20050801

• Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contact-induced activation.

  The Journal of biological chemistry 20050701

• Variation in the ability of glycoprotein IIb-IIIa antagonists to exert and maintain their inhibitory effects on the binding of fibrinogen.

  Journal of cardiovascular pharmacology 20050701

• Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050701

• Direct thrombin inhibitors.

  Current cardiology reports 20050701

• Bailout use of platelet glycoprotein IIb-IIIa inhibition during coronary stent implantation: observations from the ESPRIT trial.

  The Journal of invasive cardiology 20050701

• Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial.

  American heart journal 20050701

• Glycoprotein IIb/IIIa inhibition reduces prothrombotic events under conditions of deep hypothermic circulatory arrest.

  Thrombosis and haemostasis 20050701

• Could clopidogrel's platelet inhibition be enhanced by an increased loading dose and eptifibatide?

  Nature clinical practice. Cardiovascular medicine 20050701

• Inhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (The PharmacoDynamic Evaluation of Angiomax, Clopidogrel with or without INtegrilin [DEACON] study).

  The American journal of cardiology 20050615

• Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial).

  The American journal of cardiology 20050601

• Embolic events and char formation during pulmonary vein isolation in patients with atrial fibrillation: impact of different anticoagulation regimens and importance of intracardiac echo imaging.

  Journal of cardiovascular electrophysiology 20050601

• The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.

  American heart journal 20050601

• The impact of GP IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients.

  The Journal of invasive cardiology 20050601

• Platelet glycoprotein IIb/IIIa inhibition as adjunctive therapy during primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.

  The Journal of invasive cardiology 20050601

• Use of antiplatelet inhibitors in peripheral vascular interventions.

  Seminars in interventional radiology 20050601

• Uptake of denatured collagen into hepatic stellate cells: evidence for the involvement of urokinase plasminogen activator receptor-associated protein/Endo180.

  The Biochemical journal 20050401

• Hypothermia-induced platelet aggregation: no effect of aprotinin (trasylol) but inhibition by eptifibatide (integrilin).

  The Thoracic and cardiovascular surgeon 20050401

• Choice of GPIIb/IIIa antagonist in percutaneous coronary intervention: how should economic criteria be factored in?

  Pharmacy world & science : PWS 20050401

• Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndrome: insights from the INTERACT trial.

  American heart journal 20050401

• Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.

  Circulation 20050308

• Dual antiplatelet therapy for coronary stenting: a clear path for a research agenda.

  Circulation 20050308

• Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial).

  The American journal of cardiology 20050301

• Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials).

  The American journal of cardiology 20050301

• Safety of coronary stenting with eptifibatide and ultra-low-dose heparin.

  The American journal of cardiology 20050301

• Additive effects between platelet concentrates and desmopressin in antagonizing the platelet glycoprotein IIb/IIIa inhibitor eptifibatide.

  Transfusion 20050301

• Is platelet function as measured by Thrombelastograph monitoring in whole blood affected by platelet inhibitors?

  The journal of extra-corporeal technology 20050301

• Eptifibatide-associated acute, profound thrombocytopenia.

  The Annals of pharmacotherapy 20050201

• GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention.

  Journal of thrombosis and haemostasis : JTH 20050201

• Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors.

  Chest 20050201

• In vivo platelet redistribution and acute transient thrombocytopenia after eptifibatide injection in baboons.

  Thrombosis research 20050101

• Intra-arterial thrombolysis for acute ischemic stroke: preliminary experience with platelet glycoprotein IIb/IIIa inhibitors as adjunctive therapy.

  Neurosurgery 20050101

• Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy.

  American heart journal 20050101

• Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selection.

  Drugs 20050101

• Calpha-H...O = C hydrogen bonds contribute to the specificity of RGD cell-adhesion interactions.

  BMC structural biology 20050101

• Functional characteristic of snake venom disintegrins: potential therapeutic implication.

  Current pharmaceutical design 20050101

• Medical decision making with incomplete evidence--choosing a platelet glycoprotein IIbIIIa receptor inhibitor for percutaneous coronary interventions.

  Medical decision making : an international journal of the Society for Medical Decision Making 20050101

• Profound thrombocytopenia associated with tirofiban: case report and review of literature.

  Angiology 20050101

• The impact of adjunctive eptifibatide therapy with percutaneous coronary intervention for acute myocardial infarction.

  International journal of cardiovascular interventions 20050101

• Molecular aspects of thrombosis and antithrombotic drugs.

  Critical reviews in clinical laboratory sciences 20050101

• Is platelet adhesion assay able to quantify drug-induced platelet dysfunction?

  Seminars in thrombosis and hemostasis 20050101

• Investigation of the PADA as a method for monitoring GPIIb/IIIa inhibitors and other antiplatelet agents.

  Seminars in thrombosis and hemostasis 20050101

• Antiplatelet agents in patients undergoing percutaneous coronary intervention: how many and how much?

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20050101

• Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.

  Drugs 20050101

• The role of the platelet in the pathogenesis of atherothrombosis.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20050101

• Equipoise in the enhanced supression of the platelet IIb/IIIa receptor with integrilin trial (ESPRIT): a critical appraisal.

  Clinical trials (London, England) 20050101

• Effects of three groin compression methods on patient discomfort, distress, and vascular complications following a percutaneous coronary intervention procedure.

  Nursing research 20050101

• Bivalirudin compared with IIb/IIIa inhibitors in patients with in-stent restenosis undergoing intracoronary brachytherapy.

  Cardiovascular revascularization medicine : including molecular interventions 20050101

• Socio economic crisis and mortality. Epidemiological testimony of the financial collapse of Argentina.

  Thrombosis journal 20050101

• Inhibition of platelet activation and aggregation.

  Handbook of experimental pharmacology 20050101

• Role of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes.

  The Annals of pharmacotherapy 20041201

• A novel method to assess platelet inhibition by eptifibatide with thrombelastograph.

  Anesthesia and analgesia 20041201

• Effect of bivalirudin on length of stay in the recovery area after percutaneous coronary intervention compared with heparin alone, heparin + abciximab, or heparin + eptifibatide.

  The American journal of cardiology 20041201

• Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?

  Journal of clinical pharmacy and therapeutics 20041201

• Soluble CD40 ligand is an early initiator of inflammation after coronary intervention.

  Coronary artery disease 20041201

• Rescue in situ thrombolysis for acute coronary thromboembolism in an angiographically normal coronary artery.

  Saudi medical journal 20041201

• The use of the point of care Helena ICHOR/Plateletworks and the Accumetrics Ultegra RPFA for assessment of platelet function with GPIIB-IIIa antagonists.

  Journal of thrombosis and thrombolysis 20041201

• Bootstrap confidence intervals for medical costs with censored observations.

  Statistics in medicine 20041115

• Platelet aggregation inhibition blocks C-reactive protein and interleukin-6 (IL-6) elevation after the coronary angioplasty: effect of the -174 G/C IL-6 gene polymorphism.

  The American journal of cardiology 20041115

• Evaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitors.

  The Annals of pharmacotherapy 20041101

• Fibrinogen receptor antagonists induce conformational changes of the human platelet glycoprotein IIb.

  Cytometry. Part B, Clinical cytometry 20041101

• Development of glycoprotein IIb-IIIa antagonists: translation of pharmacodynamic effects into clinical benefit.

  Expert review of cardiovascular therapy 20041101

• Superior in-hospital and 30-day outcomes with abciximab versus eptifibatide: a contemporary analysis of 495 consecutive percutaneous coronary interventions.

  The Journal of invasive cardiology 20041101

• A comparison of clinical outcomes between Canadian and American patients after nonurgent coronary stenting.

  The Canadian journal of cardiology 20041101

• [Eptifibatide and percutaneous coronary intervention].

  Herz 20041101

• [Eptifibatide in patients with percutaneous coronary intervention in clinical practice. Results of a prospective registry].

  Herz 20041101

• A case of life-saving pharmacologic and mechanical coronary dethrombosis.

  Italian heart journal : official journal of the Italian Federation of Cardiology 20041101

• Repetitive profound thrombocytopenia after treatment with tirofiban: a case report.

  Cardiovascular drugs and therapy 20041101

• Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes.

  JAMA 20041020

• Intracranial clot lysis with intravenous microbubbles and transcranial ultrasound in swine.

  Stroke 20041001

• Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy).

  The American journal of cardiology 20041001

• Thrombocytopenia resulting from sensitivity to GPIIb-IIIa inhibitors.

  Seminars in thrombosis and hemostasis 20041001

• Comparative pharmacodynamic evaluation of eptifibatide and abciximab in patients with non-ST-segment elevation acute coronary syndromes: the TAM2 study.

  Journal of thrombosis and thrombolysis 20041001

• Platelet function predicts myocardial damage in patients with acute myocardial infarction.

  Circulation 20040914

• Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention.

  Journal of clinical pharmacology 20040901

• Spontaneous coronary artery dissection postpartum.

  The Journal of invasive cardiology 20040901

• Temporal spectrum of ischemic complications with percutaneous coronary intervention: the ESPRIT experience.

  The Journal of invasive cardiology 20040901

• Prehospital therapy with the platelet glycoprotein IIb/IIIa inhibitor eptifibatide in patients with suspected acute coronary syndromes: the Bochum feasibility study.

  Chest 20040901

• Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  Chest 20040901

• Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  Chest 20040901

• Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.

  JAMA 20040811

• Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy.

  Circulation 20040810

• Utilization of eptifibatide for treatment of severe dissections as a bail-out procedure.

  International journal of cardiology 20040801

• Comparison of bilateral thoracic artery grafting with percutaneous coronary interventions in diabetic patients.

  The Annals of thoracic surgery 20040801

• Heparin-induced thrombocytopenia presenting with thrombosis of multiple saphenous vein grafts and myocardial infarction.

  American journal of hematology 20040801

• Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions.

  Journal of the American College of Cardiology 20040721

• Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention.

  Heart (British Cardiac Society) 20040701

• Integrin clustering mechanisms explored with a soluble alphaIIbbeta3 ectodomain construct.

  Biochimica et biophysica acta 20040701

• Platelet glycoprotein IIb/IIIa inhibition and its clinical use.

  Current medicinal chemistry. Cardiovascular and hematological agents 20040701

• Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.

  Circulation 20040629

• Clopidogrel resistance: a new chapter in a fast-moving story.

  Circulation 20040629

• Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization.

  Journal of the American College of Cardiology 20040616

• Alveolar hemorrhage associated with periprocedural eptifibatide administration.

  The Journal of invasive cardiology 20040601

• Angiographic demonstration of coronary dethrombosis with eptifibatide.

  The Journal of invasive cardiology 20040601

• Effect of multielement intravascular ultrasound on the anticoagulant potency of enoxaparin.

  The American journal of cardiology 20040601

• Use of IIb/IIIa inhibitors in patients with in-stent restenosis treated with intracoronary gamma-radiation. Integrilin WRIST.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20040601

• Estimating mean response as a function of treatment duration in an observational study, where duration may be informatively censored.

  Biometrics 20040601

• Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial.

  The Canadian journal of cardiology 20040601

• Change of care for patients with acute myocardial infarctions through algorithm and standardized physician order sets.

  Critical pathways in cardiology 20040601

• Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study).

  The American journal of cardiology 20040515

• Efficiency in clinical research: assessment in vitro of potential anti-thrombotic drug interactions.

  Coronary artery disease 20040501

• Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro.

  The Journal of laboratory and clinical medicine 20040501

• Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction.

  American heart journal 20040501

• Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction.

  Journal of the American College of Cardiology 20040407

• Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial.

  American heart journal 20040401

• Incidence and predictors of major vascular complications after percutaneous coronary intervention in the glycoprotein IIb/IIIa platelet inhibitor era.

  Journal of interventional cardiology 20040401

• Progress in the field of GPIIb/IIIa antagonists.

  Current medicinal chemistry. Cardiovascular and hematological agents 20040401

• [Efficacy and safety of treatment of acute ischemic stroke with glycoprotein IIb/IIIa receptor blocker in routine clinical practice].

  Deutsche medizinische Wochenschrift (1946) 20040319

• Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin: effect on platelet function and thrombus formation.

  Journal of the American College of Cardiology 20040317

• Reversibility versus persistence of GPIIb/IIIa blocker-induced conformational change of GPIIb/IIIa (alphaIIbbeta3, CD41/CD61).

  The Journal of pharmacology and experimental therapeutics 20040301

• Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors.

  Current hematology reports 20040301

• Percutaneous coronary intervention in a patient with immune thrombocytopenia purpura.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20040301

• Glycoprotein IIb-IIIa antagonists in non-ST elevation acute coronary syndromes and percutaneous interventions: from pharmacology to individual patient's therapy: part 1: the evidence of benefit.

  Journal of cardiovascular pharmacology 20040301

• Intravenous glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: lessons from recently conducted randomized clinical trials.

  Current opinion in investigational drugs (London, England : 2000) 20040301

• Combined effects of melagatran and eptifibatide on platelet aggregation inhibition but not thrombin generation inhibition.

  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20040301

• Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function.

  Clinical therapeutics 20040301

• Platelet glycoprotein IIb/IIIa inhibitors.

  Best practice & research. Clinical haematology 20040301

• Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction.

  Journal of the American College of Cardiology 20040218

• Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention.

  The American journal of cardiology 20040215

• Safety of high-dose intravenous eptifibatide as an adjunct to internal carotid artery angioplasty and stent placement: a prospective registry.

  Neurosurgery 20040201

• GP IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20040201

• Intracoronary coagulative nightmare during recanalization of a recent total occlusion of the left anterior descending artery.

  The Journal of invasive cardiology 20040201

• Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes.

  Platelets 20040201

• Safety of glycoprotein IIb/IIIa inhibitors in urgent or emergency coronary artery bypass graft surgery.

  The Canadian journal of cardiology 20040201

• Tirofiban and eptifibatide treatment of patients presenting with acute coronary syndrome with non-ST segment elevation.

  Pharmacy world & science : PWS 20040201

• The efficacy and safety of perioperative antiplatelet therapy.

  Journal of thrombosis and thrombolysis 20040201

• Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study.

  Journal of the American College of Cardiology 20040121

• Short-term intravenous eptifibatide infusion combined with reduced dose recombinant tissue plasminogen activator inhibits platelet recruitment at sites of coronary artery injury.

  Journal of the American College of Cardiology 20040121

• Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes.

  The American journal of medicine 20040115

• Role of platelet glycoprotein polymorphisms in cardiovascular diseases.

  Naunyn-Schmiedeberg's archives of pharmacology 20040101

• Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes.

  American heart journal 20040101

• Assessment of anticoagulation using activated clotting times in patients receiving intravenous enoxaparin during percutaneous coronary intervention.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20040101

• Eptifibatide and risk of bleeding after failed thrombolysis.

  The Journal of invasive cardiology 20040101

• Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20040101

• A laboratory method for parallel determination of platelet aggregation and thrombin generation.

  Clinical laboratory 20040101

• Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.

  Thrombosis research 20040101

• Hemorheological methods in drug research.

  Clinical hemorheology and microcirculation 20040101

• Therapeutics of platelet glycoprotein IIb/IIIa receptor antagonism.

  American journal of therapeutics 20040101

• Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations.

  Clinical pharmacokinetics 20040101

• Eptifibatide-induced profound thrombocytopenia.

  Indian heart journal 20040101

• Dual coronary emboli in peripartum cardiomyopathy.

  Texas Heart Institute journal 20040101

• Eptifibatide does not influence lymphocyte activation and CRP levels in patients with undergoing coronary angioplasty.

  International journal of cardiovascular interventions 20040101

• Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin.

  Blood 20031215

• Characterization of eptifibatide during drug formulation stability assays.

  Journal of pharmaceutical and biomedical analysis 20031204

• Blockade of GPIIb/IIIa by eptifibatide and tirofiban does not alter tissue factor induced thrombin generation in human endotoxemia.

  Thrombosis and haemostasis 20031201

• Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes.

  The American journal of medicine 20031201

• A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes.

  American heart journal 20031201

• Eptifibatide-induced thrombocytopenia and circulating procoagulant platelet-derived microparticles in a patient with acute coronary syndrome.

  Journal of thrombosis and haemostasis : JTH 20031201

• The effects of aprotinin on platelet function in blood exposed to eptifibatide: an in vitro analysis.

  The journal of extra-corporeal technology 20031201

• Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis.

  Circulation 20031125

• Using eptifibatide in patients undergoing coronary angioplasty with acute myocardial infarction.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20031101

• Comparison of effectiveness and safety of three different antithrombotic regimens (bivalirudin, eptifibatide, and heparin) in preventing myocardial ischemia during percutaneous coronary intervention.

  The American journal of cardiology 20031101

• Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation.

  The American journal of cardiology 20031101

• Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention.

  American heart journal 20031101

• Association of the PURSUIT risk score with predischarge ejection fraction, angiographic severity of coronary artery disease, and mortality in a nonselected, community-based population with non-ST-elevation acute myocardial infarction.

  American heart journal 20031101

• [Platelet aggregation disorders].

  Hamostaseologie 20031101

• Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia.

  The Journal of invasive cardiology 20031101

• Application of current guidelines to the management of unstable angina and non-ST-elevation myocardial infarction.

  Circulation 20031021

• Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.

  American heart journal 20031001

• [Role of GP IIb/IIIa blockers in clinical cardiology].

  Recenti progressi in medicina 20031001

• Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin.

  Clinical therapeutics 20031001

• Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity.

  Journal of thrombosis and haemostasis : JTH 20030901

• Low molecular weight heparins combined with platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes.

  Expert opinion on investigational drugs 20030901

• Preservation of myocardial microcirculation during mechanical reperfusion for myocardial ischemia with either abciximab or eptifibatide.

  The Journal of invasive cardiology 20030901

• Microcirculatory effects of abciximab and eptifibatide: a critical appraisal.

  The Journal of invasive cardiology 20030901

• [Facilitated revascularisation in myocardial infarction with ST-segment elevation].

  Orvosi hetilap 20030810

• Percutaneous coronary interventions in octogenarians. glycoprotein IIb/IIIa receptor inhibitors' safety profile.

  Journal of the American College of Cardiology 20030806

• Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease.

  Circulation 20030805

• Assessing platelet function during treatment with glycoprotein IIb/IIIa antagonists.

  Coronary artery disease 20030801

• Platelet glycoprotein IIb/IIIa inhibition with eptifibatide: prolongation of inhibition of aggregation in acute renal failure and reversal with hemodialysis.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20030801

• [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].

  Herz 20030801

• Diminution in flow following primary stenting in the INAMI study.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20030701

• Use of GPIIb/IIIa inhibitors in cardiovascular medicine.

  Expert review of cardiovascular therapy 20030701

• Power calculations for large multi-arm placebo-controlled studies of dichotomous outcomes.

  Statistics in medicine 20030630

• Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20030615

• Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stenting.

  The American journal of cardiology 20030601

• Glycoprotein IIb/IIIa receptor inhibitors in percutaneous coronary intervention and acute coronary syndrome.

  The Annals of pharmacotherapy 20030601

• Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.

  The Journal of invasive cardiology 20030601

• Glycoprotein Wars and PIECE activists.

  The Journal of invasive cardiology 20030601

• Acute thrombocytopenia associated with eptifibatide therapy.

  The Canadian journal of cardiology 20030601

• Switching from abciximab to eptifibatide for percutaneous coronary interventions: a local analysis (SWAP study).

  The Canadian journal of cardiology 20030601

• Thrombolysis of acute peripheral arterial and venous occlusions with tenecteplase and eptifibatide: a pilot study.

  Journal of vascular and interventional radiology : JVIR 20030601

• Synergism of aspirin and heparin with a low-frequency non-invasive ultrasound system for augmentation of in-vitro clot lysis.

  Journal of thrombosis and thrombolysis 20030601

• CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation.

  Circulation research 20030516

• [New anticoagulants].

  Nederlands tijdschrift voor geneeskunde 20030510

• Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment.

  Heart (British Cardiac Society) 20030501

• GPIIb/IIIa antagonists and other anti-integrins.

  Seminars in vascular medicine 20030501

• Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial.

  Journal of the American College of Cardiology 20030416

• A propensity analysis of the impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes after percutaneous coronary intervention.

  The American journal of cardiology 20030415

• Acute stent thrombosis after early withdrawal of platelet glycoprotein IIb/IIIa antagonists: potential rebound prothrombotic effect?

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20030401

• Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.

  Journal of cardiovascular pharmacology 20030401

• Use of platelet glycoprotein IIb/IIIa inhibitors and spontaneous pulmonary hemorrhage.

  The Journal of invasive cardiology 20030401

• [GP IIb/IIIa receptor prevention medicine].

  Nihon rinsho. Japanese journal of clinical medicine 20030401

• Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention.

  Journal of interventional cardiology 20030401

• Comparative pharmacology of GP IIb/IIIa antagonists.

  Journal of thrombosis and thrombolysis 20030401

• Important triad in cardiovascular medicine: diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade.

  Circulation 20030325

• Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.

  Circulation 20030304

• Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation.

  Blood 20030301

• Comparison of shear stress-induced platelet microparticle formation and phosphatidylserine expression in presence of alphaIIbbeta3 antagonists.

  Journal of cardiovascular pharmacology 20030301

• Acute profound thrombocytopenia associated with eptifibatide therapy.

  Pharmacotherapy 20030301

• Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.

  Zeitschrift fur Kardiologie 20030301

• [Costs and cost-effectiveness of Eptifibatide in the treatment of coronary ischemic syndromes. An analysis based on the PURSUIT study].

  Zeitschrift fur Kardiologie 20030301

• Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.

  JAMA 20030219

• Introduction to 'Optimizing management of non-ST-segment elevation acute coronary syndromes'. Harmonizing advances in mechanical and pharmacologic intervention.

  Journal of the American College of Cardiology 20030219

• Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: insights from the TACTICS TIMI-18 trial.

  Journal of the American College of Cardiology 20030219

• Thrombocytopenia following treatment with platelet glycoprotein IIb/IIIa inhibitors.

  Blood 20030215

• Comparison of the i-STAT handheld activated clotting time with the Hemochron activated clotting time during and after percutaneous coronary intervention.

  The American journal of cardiology 20030215

• Comparison of one-year outcomes...ESPRIT. Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy.

  The American journal of cardiology 20030215

• [Impact of GP IIb/IIIa antagonists in interventional cardiology].

  Deutsche medizinische Wochenschrift (1946) 20030207

• Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial.

  Journal of the American College of Cardiology 20030205

• Cost effectiveness in Canada of eptifibatide treatment for acute coronary syndrome patients using PURSUIT subgroup analysis.

  The Canadian journal of cardiology 20030201

• Access to new cardiovascular therapies in Canadian hospitals: a national survey of the formulary process.

  The Canadian journal of cardiology 20030201

• Evaluation of glycoprotein IIb/IIIa inhibitors in carotid angioplasty and stenting.

  Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists 20030201

• Adjunctive use of platelet glycoprotein IIb/IIIa inhibitors for carotid angioplasty and stent placement: time to say good bye?

  Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists 20030201

• Eptifibatide-induced thrombocytopenia and coronary bypass operation.

  Journal of thrombosis and haemostasis : JTH 20030201

• Ligand binding promotes the entropy-driven oligomerization of integrin alpha IIb beta 3.

  The Journal of biological chemistry 20030131

• Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide.

  Circulation 20030121

• Anti-integrin therapy.

  Annual review of medicine 20030101

• Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial).

  The American journal of cardiology 20030101

• Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20030101

• Acute profound thrombocytopenia after use of eptifibatide for coronary stenting.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20030101

• Eptifibatide-induced acute profound thrombocytopenia presenting as refractory hypotension.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20030101

• Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study.

  Journal of the American College of Cardiology 20030101

• Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions.

  Journal of the American College of Cardiology 20030101

• Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary intervention.

  Clinical therapeutics 20030101

• [New antiaggregants and their importance for the practitioner].

  Therapeutische Umschau. Revue therapeutique 20030101

• Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.

  Drugs 20030101

• Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide.

  Clinical pharmacokinetics 20030101

• Acute procedural complications and in-hospital events after percutaneous coronary interventions: eptifibatide versus abciximab.

  Cardiovascular radiation medicine 20030101

• Risk-benefit analysis of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.

  Expert opinion on drug safety 20030101

• Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes.

  PharmacoEconomics 20030101

• Thrombocytopenia associated with antithrombotic therapy in acute coronary syndrome.

  Progress in cardiovascular nursing 20030101

• Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in the management of ischemic stroke.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20030101

• Glycoprotein IIb/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20030101

• Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20030101

• [Safety and efficacy of ANGIOGUARD protection device for the prevention of distal embolization during PCI in patients with unstable angina].

  Przeglad lekarski 20030101

• Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials.

  Circulation 20021210

• A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention.

  Journal of the American College of Cardiology 20021204

• Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion.

  The Journal of pharmacology and experimental therapeutics 20021201

• Platelet glycoprotein IIb/IIIa inhibition using eptifibatide with primary coronary stenting for acute myocardial infarction: a 30-day follow-up study.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20021201

• Bleeding associated with eptifibatide targeting higher risk patients with acute coronary syndromes: incidence and multivariate risk factors.

  Journal of clinical pharmacology 20021201

• Combined effects of eptifibatide and anticoagulants: differences between LMWH and UH or rH in thrombin generation inhibition but not in platelet aggregation inhibition.

  Thrombosis and haemostasis 20021201

• The complementary use of glycoprotein IIb/IIIa inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention.

  The Journal of invasive cardiology 20021201

• Effect of eptifibatide for acute coronary syndromes: rapid versus late administration--therapeutic yield on platelets (The EARLY Platelet Substudy).

  Journal of thrombosis and thrombolysis 20021201

• Antagonists of platelet fibrinogen receptor are less effective in carriers of Pl(A2) polymorphism of beta(3) integrin.

  European journal of pharmacology 20021101

• Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20021101

• Early use of glycoprotein IIb/IIIa-receptor inhibitors in non-ST-segment-elevation acute coronary syndromes.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20021101

• Role of glycoprotein IIb/IIIa-receptor inhibitors in managing ST-segment-elevation myocardial infarction.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20021101

• The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro.

  Platelets 20021101

• ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina).

  Circulation 20021001

• No evidence for an influence of the human platelet antigen-1 polymorphism on the antiplatelet effects of glycoprotein IIb/IIIa inhibitors.

  Pharmacogenetics 20021001

• Eptifibatide in percutaneous coronary intervention. A review.

  Minerva cardioangiologica 20021001

• Combination antiplatelet therapy: implications for pharmacists.

  Pharmacotherapy 20021001

• [Value of eptifibatide during salvage angioplasty with coronary stenting after failure of thrombolysis. Report of a series of 41 patients].

  Archives des maladies du coeur et des vaisseaux 20021001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021001

• Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study.

  Journal of the American College of Cardiology 20020918

• Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.

  Circulation 20020917

• Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.

  Blood 20020915

• Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial).

  The American journal of cardiology 20020915

• Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study).

  The American journal of cardiology 20020901

• Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa.

  Expert opinion on pharmacotherapy 20020801

• [Glycoprotein IIb/IIIa platelet blockers in acute myocardial infarct treated with primary coronary angioplasty].

  Vnitrni lekarstvi 20020801

• Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates.

  Journal of thrombosis and thrombolysis 20020801

• Glycoprotein receptor inhibitors in the management of acute coronary syndromes.

  Current cardiology reports 20020701

• Platelet glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: IIb or Not IIb, what is the question?

  The Journal of invasive cardiology 20020701

• Optimizing glycoprotein IIb/IIIa inhibition: lessons from recent randomized controlled trials.

  Internal medicine journal 20020701

• Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial.

  European heart journal 20020701

• Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100.

  American heart journal 20020701

• Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy.

  Journal of the American College of Cardiology 20020619

• Clinical pharmacology of bivalirudin.

  Pharmacotherapy 20020601

• Activated clotting times in the setting of eptifibatide use during percutaneous coronary intervention.

  Journal of thrombosis and thrombolysis 20020601

• Same-day transradial outpatient stenting with a 6-hr course of glycoprotein IIb/IIIa receptor blockade: a feasibility study.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20020501

• Use of clopidogrel loading, enoxaparin, and double-bolus eptifibatide in the setting of early percutaneous coronary intervention for acute coronary syndromes.

  The Journal of invasive cardiology 20020501

• Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.

  Critical care medicine 20020501

• Tirofiban blocks platelet adhesion to fibrin with minimal perturbation of GpIIb/IIIa structure.

  Thrombosis and haemostasis 20020501

• [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis].

  Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology 20020501

• [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis].

  Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology 20020501

• Comparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosis.

  Circulation 20020423

• Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors.

  The American journal of cardiology 20020415

• Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies.

  Thrombosis research 20020415

• Reversible thrombocytopenia associated with eptifibatide.

  The Annals of pharmacotherapy 20020401

• Indications for appropriate platelet glycoprotein IIb/IIIa inhibitor therapy.

  Annals of emergency medicine 20020401

• Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide.

  American heart journal 20020401

• Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition.

  American heart journal 20020401

• Cost efficacy of platelet glycoprotein IIb/IIIa antagonists in clinical trials and clinical practice.

  Journal of interventional cardiology 20020401

• The efficacy and safety of perioperative antiplatelet therapy.

  Journal of thrombosis and thrombolysis 20020401

• Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors.

  Thrombosis research 20020401

• A structural and dynamic investigation of the facilitating effect of glycoprotein IIb/IIIa inhibitors in dissolving platelet-rich clots.

  Circulation research 20020308

• Using a peptide inhibitor of the glycoprotein IIb/IIIa platelet receptor: initial experience in patients with acute peripheral arterial occlusions.

  AJR. American journal of roentgenology 20020301

• Platelet aggregation inhibitors for use in peripheral vascular interventions: what can we learn from the experience in the coronary arteries?

  Journal of vascular and interventional radiology : JVIR 20020301

• Recent advances in antiplatelet agents.

  Current medicinal chemistry 20020301

• Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta3 integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin.

  Circulation 20020212

• Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial.

  Journal of the American College of Cardiology 20020206

• Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention.

  JAMA 20020206

• Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?

  Circulation 20020205

• Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker.

  European heart journal 20020201

• [Eptifibatide blocks the increase in C-reactive protein concentration after coronary angioplasty].

  Revista espanola de cardiologia 20020201

• The role of alpha(v)beta3 integrins in vascular healing.

  Thrombosis and haemostasis 20020201

• The WRIST series--what have we learnt?

  Herz 20020201

• Glycoprotein IIb/IIIa inhibitors.

  Intensive & critical care nursing 20020201

• The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors.

  Journal of interventional cardiology 20020201

• Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.

  Circulation 20020122

• Platelet glycoprotein IIb/IIIa inhibitor effect examined in 2 studies.

  Circulation 20020122

• A synthetic polymer matrix for the delayed or pulsatile release of water-soluble peptides.

  Journal of controlled release : official journal of the Controlled Release Society 20020117

• Activated monocytes induce smooth muscle cell death: role of macrophage colony-stimulating factor and cell contact.

  Circulation 20020115

• Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy.

  European heart journal 20020101

• Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy.

  American heart journal 20020101

• In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin.

  The American journal of cardiology 20020101

• Early recovery of microvascular perfusion induced by t-PA in combination with abciximab or eptifibatide during postischemic reperfusion.

  BMC cardiovascular disorders 20020101

• Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.

  Drugs 20020101

• Platelet glycoprotein IIb/IIIa receptor blockade with integrilin (eptifibatide) for early postinfarction angina in a patient with coronary arterial ectasia.

  Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20020101

• Safety and efficacy of combined use of low molecular weight heparin (enoxaparin, lovenox) and glycoprotein IIb/IIIa receptor antagonist (eptifibatide, integrelin) during nonemergent coronary and peripheral vascular intervention.

  American journal of therapeutics 20020101

• In vitro anti-aggregatory effects of the GP IIb/IIIa antagonist eptifibatide on feline platelets.

  Journal of veterinary internal medicine 20020101

• Inhibition of shear-stress-induced platelet aggregation and phosphotyrosine signaling by GPIIb-IIIa antagonists.

  Annals of biomedical engineering 20020101

• Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy).

  Cardiology 20020101

• Emergency coronary artery bypass surgery in the era of glycoprotein IIb/IIIa receptor antagonist use.

  Journal of cardiac surgery 20020101

• [Platelet inhibitors: old and new].

  La Tunisie medicale 20020101

• Platelet inhibition after glycoprotein IIb/IIIa inhibitor therapy.

  Circulation 20011218

• Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes.

  Lancet (London, England) 20011208

• Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.

  Circulation 20011204

• A risk stratification scheme for selection of a glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention based on clinical and angiographic criteria.

  The American journal of cardiology 20011201

• GP IIb/IIIa inhibitors in coronary artery disease management: what the latest trials tell us.

  Cleveland Clinic journal of medicine 20011201

• Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study).

  The American journal of cardiology 20011115

• ESPRIT in context: pharmacology matters!

  European heart journal 20011101

• Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT--(Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II Trial.

  The American journal of cardiology 20011101

• Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non-ST-segment elevation acute coronary syndromes: results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials.

  Current opinion in cardiology 20011101

• [Indications for intravenous GPIIb/IIIa receptor inhibitors in acute coronary syndrome without prolonged ST syndrome].

  Archives des maladies du coeur et des vaisseaux 20011101

• Modulation of platelet aggregation in baboons: implications for mixed chimerism in xenotransplantation. I. The roles of individual components of a transplantation conditioning regimen and of pig peripheral blood progenitor cells.

  Transplantation 20011015

• Bleeding in a patient receiving platelet aggregation inhibitors.

  Anesthesia and analgesia 20011001

• Eptifibatide and abciximab exhibit equivalent antiplatelet efficacy in an experimental model of stenting in both healthy volunteers and patients with coronary artery disease.

  Journal of cardiovascular pharmacology 20011001

• Increased reperfusion by glycoprotein IIb/IIIa receptor antagonist administration in case of unsuccessful and failed thrombolysis in patients with acute myocardial infarction: a pilot study.

  Italian heart journal : official journal of the Italian Federation of Cardiology 20011001

• Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban.

  Journal of thrombosis and thrombolysis 20011001

• Comparison of GP IIB/IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer.

  Journal of thrombosis and thrombolysis 20011001

• Oral glycoprotein IIb/IIa antagonists for unstable angina--is there still a chance for the oral substances?

  Thrombosis research 20010930

• Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation.

  Circulation 20010918

• Differential inhibition of adenosine diphosphate- versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics.

  Blood 20010901

• Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial.

  Journal of the American College of Cardiology 20010901

• Severe thrombocytopenia possibly related to readministration of eptifibatide.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20010901

• [Platelet glycoprotein IIb/IIIa blockade with eptifibatide in angioplasty followed by stent implantation at 6 month in the ESPRIT study].

  Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology 20010901

• Association of eptifibatide and acute profound thrombocytopenia.

  The American journal of cardiology 20010815

• There is synergism between high-intensity, low-frequency ultrasound and streptokinase but not with eptifibatide, heparin, and aspirin. Differential effects on fresh and aged blood clots. An in vitro study.

  Thrombosis research 20010815

• Binding of a fibrinogen mimetic stabilizes integrin alphaIIbbeta3's open conformation.

  Protein science : a publication of the Protein Society 20010801

• Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (alphaIIb/beta3) receptor-directed platelet inhibition.

  American heart journal 20010801

• Comparison of eptifibatide and abciximab with decision analysis.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20010801

• Platelet glycoprotein IIb/IIIa-receptor inhibitors in patients with acute coronary syndromes or undergoing percutaneous coronary interventions: a review.

  Clinical therapeutics 20010801

• [Optimal thrombolysis].

  Zeitschrift fur Kardiologie 20010801

• Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population.

  Circulation 20010731

• Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin.

  Circulation 20010731

• AlphaIIb's cytoplasmic domain is not required for ligand-induced clustering of integrin alphaIIbbeta3.

  Biochimica et biophysica acta 20010725

• Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT.

  Circulation 20010724

• Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention.

  Circulation 20010724

• Assembly of a fibronectin matrix by adherent platelets stimulated by lysophosphatidic acid and other agonists.

  Blood 20010701

• Emergency room administration of eptifibatide before primary angioplasty for ST elevation acute myocardial infarction and its effect on baseline coronary flow and procedure outcomes.

  The American journal of cardiology 20010701

• Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trial.

  The American journal of cardiology 20010701

• Extensive thrombus prior to elective percutaneous coronary intervention.

  The Journal of invasive cardiology 20010701

• Impact of abciximab versus eptifibatide on length of hospital stay for PCI patients.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20010701

• Glycoprotein IIb/IIIa inhibitors: more different than alike?

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20010701

• Anti-GPIIb/IIIa drugs: current strategies and future directions.

  Thrombosis and haemostasis 20010701

• Mechanisms of thrombotic microangiopathy following xenogeneic hematopoietic progenitor cell transplantation.

  Transplantation 20010615

• Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy.

  The American journal of cardiology 20010601

• Successful use of eptifibatide as an adjunct to coronary stenting in a patient with abciximab-associated acute profound thrombocytopenia.

  The Journal of invasive cardiology 20010601

• Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy.

  Circulation 20010529

• Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.

  Circulation 20010529

• Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial.

  JAMA 20010516

• Stabilization of eptifibatide by cosolvents.

  International journal of pharmaceutics 20010507

• Drug-company sponsorship and the Declaration of Helsinki.

  Lancet (London, England) 20010505

• Open-label phase I clinical study to assess the safety of intravenous eptifibatide in patients undergoing internal carotid artery angioplasty and stent placement.

  Neurosurgery 20010501

• Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes.

  Cardiology clinics 20010501

• Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.

  Journal of thrombosis and thrombolysis 20010501

• Antiplatelet agents in tissue factor-induced blood coagulation.

  Blood 20010415

• A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20010401

• Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting.

  Journal of the American College of Cardiology 20010401

• In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests.

  Thrombosis research 20010401

• Greater inhibition of platelet procoagulant activity by antibody-derived glycoprotein IIb--IIIa inhibitors than by peptide and peptidomimetic inhibitors.

  British journal of haematology 20010401

• [Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa inhibitors].

  Herz 20010401

• [GPIIb-IIIa inhibitors].

  Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine 20010401

• Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.

  Journal of thrombosis and thrombolysis 20010401

• New approaches to diagnosis and management of unstable angina and non-ST-segment elevation myocardial infarction.

  Archives of internal medicine 20010312

• Comparative specificity of platelet alpha(IIb)beta(3) integrin antagonists.

  The Journal of pharmacology and experimental therapeutics 20010301

• Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.

  The American journal of cardiology 20010301

• Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention.

  The American journal of cardiology 20010301

• Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial.

  American heart journal 20010301

• Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial.

  American heart journal 20010301

• Initial experience with a newer generation coronary stent.

  The Journal of invasive cardiology 20010301

• Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.

  Thrombosis and haemostasis 20010301

• Unexpected flow cytometric results with two small GPIIb/IIIa blockers: eptifibatide and tirofiban.

  Thrombosis and haemostasis 20010301

• Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function.

  Journal of the American College of Cardiology 20010301

• Utility of mechanical rheolysis as an adjunct to rescue angioplasty and platelet inhibition in acute myocardial infarction and cardiogenic shock: a case report.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20010201

• [Economic evaluation of eptifibatide].

  Revista espanola de cardiologia 20010201

• Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators.

  Journal of the American College of Cardiology 20010201

• [Integrin-ligands binding reaction upregulates the antioxidant activity of rabbit bronchial epithelial cells].

  Sheng li xue bao : [Acta physiologica Sinica] 20010201

• Rheolytic thrombectomy for in-stent thrombosis: creating a diagnostic window.

  Journal of interventional cardiology 20010201

• [Eptifibatide (Integrilin)].

  Ugeskrift for laeger 20010122

• [Update on the treatment with platelet antiaggregation agents].

  Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology 20010101

• [Inhibitors of platelet glycoprotein IIb-IIIa in cardiology].

  Vojnosanitetski pregled 20010101

• Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized placebo-controlled study.

  Indian heart journal 20010101

• The role of glycoprotein IIb/IIIa inhibition in the management of acute coronary syndromes.

  Heart & lung : the journal of critical care 20010101

• Intravenous glycoprotein IIb/IIIa inhibition in non-ST segment elevation acute coronary syndromes.

  Progress in cardiovascular diseases 20010101

• Determination of the falloff constant (k(f)) from modeling biochemical marker release: a new variable for discriminating therapies.

  Cardiovascular toxicology 20010101

• [Glycoprotein IIb/IIIa inhibitors in unstable angina].

  Annales de cardiologie et d'angeiologie 20010101

• [Unstable angina in the elderly].

  Annales de cardiologie et d'angeiologie 20010101

• Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.

  Journal of medicinal chemistry 20000921

• Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials.

  The American journal of medicine 20000815